Group items tagged

new (March 24th) report in Clinical Cancer Research, a journal of the American Association for Cancer Research, shows that Omega-3 fatty acids appear protective against advanced prostate cancer. Dr. John S. Witte, Ph.D., professor of epidemiology and biostatistics at the University of California San Francisco, says that previous research has shown protection against prostate cancer, but that this is one of the first studies to show protection against advanced prostate cancer.

Sharing experiences, support and advise for men with advanced & recurrent Prostate Cancer

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN. J Dtsch Dermatol Ges. 2008 Dec;6(12):1066-9. English, German. PMID: 19138272 DOI: 10.1111/j.1610-0387.2008.06861.x

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Ann Oncol. 2008 Nov;19(11):1969-74. Epub 2008 Jun 9. Erratum in: Ann Oncol. 2008 Dec;19(12):2095. PMID: 18544557 doi:10.1093/annonc/mdn377

B. G. Redman, P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer, and S. D. Merajver Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1666 - 1672.

Specenier P, Vermorken JB. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol. 2007 May;19(3):195-201. PMID: 17414636 [PubMed - in process]

Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Cerchietti LC, Navigante AH, Castro MA. Nutr Cancer. 2007;59(1):14-20. PMID: 17927497

Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Tsang KW, Lam CL, Yan C, Mak JC, Ooi GC, Ho JC, Lam B, Man R, Sham JS, Lam WK. Respir Med. 2003 Jun;97(6):618-24. PMID: 12814145 doi:10.1053/rmed.2003.1490

Elevated levels of the inflammatory marker C-reactive protein (CRP) are associated with an increased risk of death in men with advanced prostate cancer, according to findings from a subanalysis of the ASCENT (AIPC Study of Calcitriol Enhancing Taxotere) t

Our findings suggest that administration of n-3 FA (EPA and DHA) in doses of at least 1.5 g/day for a prolonged period of time to patients with advanced cancer is associated with an improvement in clinical, biological and QoL parameters. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C. Br J Nutr. 2007 May;97(5):823-31. Review. PMID: 17408522 doi:10.1017/S000711450765795X

Like many women with an advanced form of the disease, Lange says she feels alienated from the larger breast cancer community, and out-of-place at the countless events held each October for breast cancer Awareness Month.

Mesothelioma Expert identifies three main areas of growth in medical research.

Online Cancer blog tracks information on the advances in the study of cancers, and also other aspects of cancer related issues that concerns majority of people. Learn the latest information and treatment methods on prostate cancer, breast cancer, lung cancer, skin cancer, colon cancer, ovarian cancer, pancreatic cancer, liver cancer, throat cancer.

(NaturalNews) An anti-cancer compound found in broccoli and cabbage stops breast cancer by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a recent study from the University of California, Berkley. That compound was indole-3-carbinol (I3C). Today, scientists have found that diindolymethane (DIM), a molecule found in I3C, is the chemoprotective compound that gets the job done. According to them, DIM is the better choice for women wanting to halt breast

Online Cancer blog tracks information on the advances in the study of cancers, and also other aspects of cancer related issues that concerns majority of people. Learn the latest information and treatment methods on prostate cancer, breast cancer, lung cancer, skin cancer, colon cancer, ovarian cancer, pancreatic cancer, liver cancer, throat cancer.

February 14, 2009 - (BRONX, NY) - Scientists at Albert Einstein College of Medicine of Yeshiva University have piggybacked antibodies onto radioactive payloads to deliver doses of radiation that selectively target and destroy microbial and HIV-infected cells. The experimental treatment - called radioimmunotherapy, or RIT - holds promise for treating various infectious diseases, including HIV and cancers caused by viruses. The research was presented today at the annual meeting of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and the publishers of the journal Science.

ACOR is an Internet-based public charity dedicated to improve the quality of care provided to cancer patients and the quality of life of patients, survivors and their caregivers. ACOR leverages its wide technological and biomedical resource expertise to be a reliable source of knowledge, support and community in a relentless worldwide campaign to empower those suffering from the disease. ACOR achieves its mission by constantly investing in advanced technologies and improving them to: Provide uninterrupted open access to a large nexus of online peer support groups (Health eCommunities) it creates and manages, Host a number of exceptional patient-centered websites. Conduct breakthrough research.

"Worcester, MA - Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology. Prostate cancer cells are often resistant to cell death. Researchers led by Dr. Dario C. Altieri of the University of Massachusetts Medical School, therefore, explored the role of TRAP-1, a protein thought to regulate cell death, in prostate cancer survival. TRAP-1 was highly expressed in both high-grade human prostate cancer lesions and mouse models of prostate cancer, but not in benign or normal prostate tissue. In addition, TRAP-1 overexpression in non-cancer prostate cells inhibited cell death, whereas TRAP-1-deficient prostate cancer cells had enhanced levels of cell death. Moreover, treatment with Gamitrinib, which inhibits TRAP-1, resulted in prostate cancer cell death, but not death of non-cancerous prostate cells. Therefore, targeting TRAP-1 via Gamitrinib treatment may be a viable therapeutic strategy for patients with advanced prostate cancer."

Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Kidd P. Altern Med Rev. 2003 Aug;8(3):223-46. Review. PMID: 12946237 Th1 pathways typically produce activation of cytotoxic T lymphocytes (Tc), NK cells, macrophages, and monocytes, all of which can attack cancer cells and generally defend against tumors.55 IFN-gamma and other Th1 cytokines are typically lower in advanced cancer patients, while the Th2 marker IL-4 can be higher or unchanged